How has been the historical performance of Aarey Drugs?

Answer:The historical performance of Aarey Drugs shows a fluctuating trend in net sales and profits over the years, with a notable increase in net sales for the year ending March 2025 at 473.94 Cr, compared to 395.62 Cr in March 2024 and 418.96 Cr in March 2023. However, this increase in sales has not translated into consistent profitability, as the profit after tax for March 2025 was 4.02 Cr, down from 4.68 Cr in March 2024 and 3.78 Cr in March 2023. The operating profit margin has also decreased, standing at 0.47% in March 2025, compared to 1.13% in March 2024 and 1.85% in March 2023. The company has faced rising raw material costs, which reached 472.87 Cr in March 2025, contributing to a total expenditure of 471.70 Cr for the same period. Despite these challenges, the company has maintained a stable equity capital of 28.05 Cr since March 2024 and has seen an increase in reserves to 107.96 Cr in March 2025.

Breakdown:
Aarey Drugs has experienced variable financial performance over the years, with net sales peaking at 473.94 Cr in March 2025, a significant rise from the previous year but lower than the figures from March 2022. The total operating income mirrored this trend, reflecting the same sales figures. However, the company's operating profit has shown a downward trajectory, with an operating profit of 12.05 Cr in March 2025, which is an increase from the previous year but lower than earlier years. The profit before tax also saw a slight increase to 6.10 Cr in March 2025, while profit after tax decreased to 4.02 Cr. The operating profit margin has declined, indicating rising costs, particularly in raw materials, which have increased significantly over the years. Despite these challenges, Aarey Drugs has maintained a steady equity capital and increased its reserves, showcasing some financial stability amidst fluctuating profitability.